A cancer vaccine to boost body’s natural defences to fight chordoma and head and neck cancer

Project Information

MaxONCO

Grant agreement ID: 880194

DOI 10.3030/880194

Project closed

EC signature date 31 October 2019

Start date 1 January 2020

End date 31 December 2022

Funded under

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Total cost € 3 979 000,00

EU contribution € 2 785 300,00

Coordinated by

MAXIVAX SA
Switzerland

Publications

Peer reviewed articles (1)

Immortalized human myoblast cell lines for the delivery of therapeutic proteins using encapsulated cell technology

Author(s): Aurelien Lathuiliere, Remi Vernet, Emily Charrier, Muriel Urwyler, Olivier Von Rohr, Marie-Claude Belkouch, Valentin Saingier, Thomas Bouvarel, Davy Guillarme, Adrien Engel, Patrick Salmon, Thomas Laumonier, Julien Grogg, Nicolas Mach
Published in: Molecular Therapy Methods & Clinical Development, Issue Volume 26, 8 Sept 2022, 2022, ISSN 2329-0501
Publisher: Cell Press
DOI: 10.1016/j.omtm.2022.07.017